Course Director: Pravin U. Dugel, MD
Release Date: March 31, 2019
Expiration Date: March 31, 2020
Credits Available: Physicians – maximum of 0.5 AMA PRA Category 1 Credits™
Jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education
Supported by an independent educational grant from Novartis Pharmaceuticals Corporation
Release Date: March 31, 2019; Valid for credit through March 31, 2020
Estimated Time to Complete Activity: 30 minutes
This activity has been designed to meet the educational needs of retina specialists, comprehensive ophthalmologists and other healthcare professionals involved in the treatment of patients with nAMD.
Upon completion of this activity, participants should be better able to:
- Discuss goals and challenges in the treatment of nAMD
- Utilize treatment- and patient-specific considerations to customize anti-VEGF therapy for nAMD patients
- Describe the efficacy, safety, and treatment burden of current and emerging anti-VEGF therapies for nAMD
- Physicians — maximum of 0.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Pravin U. Dugel, MD
Retinal Consultants of Arizona LTD
Retinal Research Institute LLC
USC Roski Eye Institute
Keck School of Medicine
University of Southern California
Los Angeles, California
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Catamount Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Pravin U. Dugel, MD
Reported Financial Relationship
Scientific Advisory Board
Acucela, Aerpio, Alcon Pharmaceutical, Alcon Surgical (RACII), Alimera Sciences, AMO, Annidis, ArticDX, Avalanche, CDR-Life Inc., Clearside Biomedical, Digisight, DOSE Medical, Genentech, Graybug Vision, Lutronic, Lux BioScience, MacuSight, NeoVista, Neurotech, Novartis, Omeros, Ophthotech, Opthea, Orbis International, Roche, Santen, Shire Human Genetics, Stealth Biotherapeutics, Thrombogenics, TrueVision.
Abfero, Acucela, Aerie Pharmaceutical, Aerpio, Alcon Pharmaceutical, Alcon Surgical, Alimera Sciences, Allergan, Amgen, Annidis, ArticDx, Bausch + Lomb Pharma, Boehringer Ingelheim, ByeOnics, Chengdu Kanghong Biotechnology, Clearside Biomedical, DOSE Medical, DigiSight, Gemini Pharmaceutical, Genentech, Graybug Vision, Ionis, Irenix, Kodiak Sciences, Lutronic, Lux BioScience, MacuSight, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Ophthotech, Opthea, Optovue, ORA, PanOptica, Pentavision, Pieris Pharmaceutical, pSivida Corporation, RegenexBio, Roche, Santen, Inc., SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenics, TopCon, Zeiss Group.
Alimera, Aerpio, Annidis, ArctixDx, Clearside Biomedical, Digisight, Irenix, Ophthotech, PanOptica, TrueVision
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Planners and Managers
PIM planners and managers have nothing to disclose. The Catamount Medical Education planners and managers have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period March 31, 2019, through March 31, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 66% or better and the activity evaluation, your certificate will be made available immediately.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.